Latest & greatest articles for autism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on autism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on autism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Autism

Autism is a neurodevelopmental disorder (a type of mental disorder) characterised by difficult social interaction, impaired communication (both verbal and non-verbal), and restricted and repetitive behaviours. It forms part of the broader autism spectrum disorder (ASD), a range of similar conditions, including Asperger syndrome.

Autism is a condition that begins from early childhood and is often suspected and diagnosed by ages 1-3. It is a lifelong disability that affects how people interact with others.

Autism causes and treatment

There have been many misconceptions as to what causes autism in the past such as the MMR vaccine and diet. Extensive research and clinical trials have concluded that none of these factors cause autism or ASD. However, the real cause is little understood but research is starting to unpick potential factors such as genetics, pollution and other environmental factors. A current favoured idea is that genes inherited from a child’s parents can make them more vulnerable to developing autism, some researchers suggest that the disorder will only develop when triggered by environmental factors.

The exact cause of autism spectrum disorder is unknown, however research into the disorder suggest that it is caused by several genetic and environmental factors. Genes inherited from a child’s parents can make them more vulnerable to developing autism, some researchers suggest that the disorder will only develop when triggered by environmental factors. Read more in clinical papers on autism.

Autism can be managed with a combination of prescribed medicines and behavioural treatment, depending on the severity of the disorder. Read about clinical trials and medical advancements for the treatment of autism on Trip.

Hot topics in Trip

Users of Trip frequently look at topics around adolescents, therapies, behaviour and screening. They also explore such topics as omega-3 fatty acids, SSRIs and aripiprazole. All these topics, and more, can be easily searched for within Trip.

Top results for autism

101. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder Full Text available with Trip Pro

Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder Hyperactivity, impulsiveness, and distractibility are common problems in children with autism spectrum disorder (ASD). Extended-release guanfacine is approved for children with attention deficit hyperactivity disorder but not well studied in ASD.In a multisite, randomized clinical trial, extended-release guanfacine was compared with placebo in children with ASD accompanied by hyperactivity, impulsiveness

2015 EvidenceUpdates Controlled trial quality: uncertain

102. Molecular Diagnostic Yield of Chromosomal Microarray Analysis and Whole-Exome Sequencing in Children With Autism Spectrum Disorder. Full Text available with Trip Pro

Molecular Diagnostic Yield of Chromosomal Microarray Analysis and Whole-Exome Sequencing in Children With Autism Spectrum Disorder. The use of genome-wide tests to provide molecular diagnosis for individuals with autism spectrum disorder (ASD) requires more study.To perform chromosomal microarray analysis (CMA) and whole-exome sequencing (WES) in a heterogeneous group of children with ASD to determine the molecular diagnostic yield of these tests in a sample typical of a developmental pediatric

2015 JAMA

103. Telehealth for Autism Spectrum Disorder Diagnosis in Pediatric Patients: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines

of telehealth for diagnosis of pediatric patients with suspected Autism Spectrum Disorder? Key Message One randomized controlled trial and three non-randomized studies were identified regarding telehealth diagnosis of Autism Spectrum Disorder in pediatric patients. Tags adolescent, autistic disorder, child, child development disorders, infant, pediatrics, remote consultation, telemedicine, videoconferencing, ehealth, , Pervasive, Remote, Telemonitor, Telepsychiatry Files Rapid Response Summary of Abstracts (...) Telehealth for Autism Spectrum Disorder Diagnosis in Pediatric Patients: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Telehealth for Autism Spectrum Disorder Diagnosis in Pediatric Patients: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Telehealth for Autism Spectrum Disorder Diagnosis in Pediatric Patients: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Telehealth for Autism Spectrum Disorder Diagnosis in Pediatric Patients

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

104. [Efficacy of early intensive behavioral intervention in autism spectrum disorders]

[Efficacy of early intensive behavioral intervention in autism spectrum disorders] Eficacia de las terapias conductuales tempranas e intensivas en los Trastornos del Espectro Autista [Efficacy of early intensive behavioral intervention in autism spectrum disorders] Eficacia de las terapias conductuales tempranas e intensivas en los Trastornos del Espectro Autista [Efficacy of early intensive behavioral intervention in autism spectrum disorders] Gonzalez L, Pichon-Riviere A, Augustovski F (...) of early intensive behavioral intervention in autism spectrum disorders] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 404. 2015 Authors' objectives To assess the available evidence on the efficacy, safety and issues related to coverage policies for the use of early intensive behavioral interventions in patients with autism spectrum disorder. Authors' conclusions The quality of the evidence found is low. It shows that an EIBI program could

2015 Health Technology Assessment (HTA) Database.

105. Genetic testing for developmental disabilities, intellectual disability, and autism spectrum disorder

Genetic testing for developmental disabilities, intellectual disability, and autism spectrum disorder Genetic testing for developmental disabilities, intellectual disability, and autism spectrum disorder Genetic testing for developmental disabilities, intellectual disability, and autism spectrum disorder Sun F, Oristaglio J, Levy SE, Hakonarson H, Sullivan N, Fontanarosa J, Schoelles KM Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Sun F, Oristaglio J, Levy SE, Hakonarson H, Sullivan N, Fontanarosa J, Schoelles KM. Genetic testing for developmental disabilities, intellectual disability, and autism spectrum disorder. Rockville: Agency for Healthcare Research and Quality (AHRQ). Technical Brief No. 23. 2015 Authors' objectives This Technical Brief collects and summarizes information on genetic tests clinically available

2015 Health Technology Assessment (HTA) Database.

106. Chelation for autism spectrum disorder (ASD). (Abstract)

Chelation for autism spectrum disorder (ASD). It has been suggested that the severity of autism spectrum disorder (ASD) symptoms is positively correlated with the level of circulating or stored toxic metals, and that excretion of these heavy metals, brought about by the use of pharmaceutical chelating agents, results in improved symptoms.To assess the potential benefits and adverse effects of pharmaceutical chelating agents (referred to as chelation therapy throughout this review) for autism (...) symptoms.This review included data from only one study, which had methodological limitations. As such, no clinical trial evidence was found to suggest that pharmaceutical chelation is an effective intervention for ASD. Given prior reports of serious adverse events, such as hypocalcaemia, renal impairment and reported death, the risks of using chelation for ASD currently outweigh proven benefits. Before further trials are conducted, evidence that supports a causal link between heavy metals and autism

2015 Cochrane

107. Chelation for autism spectrum disorder (ASD). Full Text available with Trip Pro

Chelation for autism spectrum disorder (ASD). It has been suggested that the severity of autism spectrum disorder (ASD) symptoms is positively correlated with the level of circulating or stored toxic metals, and that excretion of these heavy metals, brought about by the use of pharmaceutical chelating agents, results in improved symptoms.To assess the potential benefits and adverse effects of pharmaceutical chelating agents (referred to as chelation therapy throughout this review) for autism (...) symptoms.This review included data from only one study, which had methodological limitations. As such, no clinical trial evidence was found to suggest that pharmaceutical chelation is an effective intervention for ASD. Given prior reports of serious adverse events, such as hypocalcaemia, renal impairment and reported death, the risks of using chelation for ASD currently outweigh proven benefits. Before further trials are conducted, evidence that supports a causal link between heavy metals and autism

2015 Cochrane

108. Special report: early intensive behavioral intervention and other behavioral interventions for autism spectrum disorder

Special report: early intensive behavioral intervention and other behavioral interventions for autism spectrum disorder Special report: early intensive behavioral intervention and other behavioral interventions for autism spectrum disorder Special report: early intensive behavioral intervention and other behavioral interventions for autism spectrum disorder BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation BlueCross BlueShield Association. Special report: early intensive behavioral intervention and other behavioral interventions for autism spectrum disorder. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 30(1). 2015 Authors' objectives This Special Report has 2 goals: (1) to review comparative studies of EIBI and assess patient or intervention characteristics that might moderate treatment effects; and (2

2015 Health Technology Assessment (HTA) Database.

109. Autism phenotype versus registered diagnosis in Swedish children: prevalence trends over 10 years in general population samples. Full Text available with Trip Pro

Autism phenotype versus registered diagnosis in Swedish children: prevalence trends over 10 years in general population samples. To compare the annual prevalence of the autism symptom phenotype and of registered diagnoses for autism spectrum disorder during a 10 year period in children.Population based study.Child and Adolescent Twin Study and national patient register, Sweden.19, 993 twins (190 with autism spectrum disorder) and all children (n=1,078,975; 4620 with autism spectrum disorder (...) ) born in Sweden over a 10 year period from 1993 to 2002.Annual prevalence of the autism symptom phenotype (that is, symptoms on which the diagnostic criteria are based) assessed by a validated parental telephone interview (the Autism-Tics, ADHD and other Comorbidities inventory), and annual prevalence of reported diagnoses of autism spectrum disorder in the national patient register.The annual prevalence of the autism symptom phenotype was stable during the 10 year period (P=0.87 for linear time

2015 BMJ

110. Effect of parent training vs parent education on behavioral problems in children with autism spectrum disorder: a randomized clinical trial. Full Text available with Trip Pro

Effect of parent training vs parent education on behavioral problems in children with autism spectrum disorder: a randomized clinical trial. Disruptive behavior is common in children with autism spectrum disorder. Behavioral interventions are used to treat disruptive behavior but have not been evaluated in large-scale randomized trials.To evaluate the efficacy of parent training for children with autism spectrum disorder and disruptive behavior.This 24-week randomized trial compared parent (...) training (n = 89) to parent education (n = 91) at 6 centers (Emory University, Indiana University, Ohio State University, University of Pittsburgh, University of Rochester, Yale University). We screened 267 children; 180 children (aged 3-7 years) with autism spectrum disorder and disruptive behaviors were randomly assigned (86% white, 88% male) between September 2010 and February 2014.Parent training (11 core, 2 optional sessions; 2 telephone boosters; 2 home visits) provided specific strategies

2015 JAMA Controlled trial quality: predicted high

111. Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. Full Text available with Trip Pro

Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. Despite research showing no link between the measles-mumps-rubella (MMR) vaccine and autism spectrum disorders (ASD), beliefs that the vaccine causes autism persist, leading to lower vaccination levels. Parents who already have a child with ASD may be especially wary of vaccinations.To report ASD occurrence by MMR vaccine status in a large sample of US children who have older siblings (...) with and without ASD.A retrospective cohort study using an administrative claims database associated with a large commercial health plan. Participants included children continuously enrolled in the health plan from birth to at least 5 years of age during 2001-2012 who also had an older sibling continuously enrolled for at least 6 months between 1997 and 2012.MMR vaccine receipt (0, 1, 2 doses) between birth and 5 years of age.ASD status defined as 2 claims with a diagnosis code in any position for autistic

2015 JAMA

112. Association of maternal diabetes with autism in offspring. Full Text available with Trip Pro

Association of maternal diabetes with autism in offspring. Information about the association of maternal diabetes and autism spectrum disorders (ASDs) in offspring is limited, with no report on the importance of timing of exposure during gestation.To assess ASD risk associated with intrauterine exposure to preexisting type 2 diabetes and gestational diabetes mellitus (GDM) by gestational age at GDM diagnosis.Retrospective longitudinal cohort study including 322 323 singleton children born

2015 JAMA

113. Parent-Implemented Social Intervention for Toddlers With Autism: An RCT Full Text available with Trip Pro

Parent-Implemented Social Intervention for Toddlers With Autism: An RCT To compare the effects of two 9-month parent-implemented interventions within the Early Social Interaction (ESI) Project. Both individual-ESI, offered 2 or 3 times per week at home or in the community, and group-ESI, offered once per week in a clinic, taught parents how to embed strategies to support social communication throughout everyday activities.Participants in the randomized controlled trial included 82 children (...) diagnosed with autism spectrum disorder at 16 to 20 months. Children were matched on pretreatment nonverbal developmental level and pairs were randomly assigned to treatment condition. Child outcomes included measures of social communication, autism symptoms, adaptive behavior, and developmental level. Child outcomes are reported from baseline to the end of the 9-month interventions.Children in individual-ESI showed differential change on a standardized examiner-administered observational measure

2015 EvidenceUpdates Controlled trial quality: uncertain

114. Quantitative autistic traits are transmitted intergenerationally and increase risk for autism spectrum disorders

Quantitative autistic traits are transmitted intergenerationally and increase risk for autism spectrum disorders Quantitative autistic traits are transmitted intergenerationally and increase risk for autism spectrum disorders | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Quantitative autistic traits are transmitted intergenerationally and increase risk for autism spectrum disorders Article Text Causes and risk factors Quantitative

2015 Evidence-Based Mental Health

115. Gene panels in autistic spectrum disorders

with autistic spectrum disorders. The different international clinical practice guidelines consulted do not specifically mention them. The international coverage policies surveyed do not provide coverage and consider them at experimental stage. Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Autism Spectrum Disorder; Autistic Disorder; Child Development Disorders, Pervasive; Humans Language Published Spanish Country of organisation Argentina English summary (...) Gene panels in autistic spectrum disorders Gene panels in autistic spectrum disorders Gene panels in autistic spectrum disorders Secco A, Rey- Ares L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Secco A, Rey- Ares L, Pichon-Riviere

2015 Health Technology Assessment (HTA) Database.

116. Equine therapy and other Equine-related therapies in developmental disorders, autism spectrum disorders and cerebral palsy

benefit. Healthcare sponsors surveyed do not cover this technology because they consider it experimental. Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Autism Spectrum Disorder; Autistic Disorder; Cerebral Palsy; Developmental Disabilities; Equine-Assisted Therapy; Humans Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness (...) Equine therapy and other Equine-related therapies in developmental disorders, autism spectrum disorders and cerebral palsy Equine therapy and other Equine-related therapies in developmental disorders, autism spectrum disorders and cerebral palsy Equine therapy and other Equine-related therapies in developmental disorders, autism spectrum disorders and cerebral palsy Oubiña M, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L Record Status

2015 Health Technology Assessment (HTA) Database.

117. Growing evidence that maternal gestational diabetes increases risk of autism in offspring

Growing evidence that maternal gestational diabetes increases risk of autism in offspring Growing evidence that maternal gestational diabetes increases risk of autism in offspring | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Growing evidence that maternal gestational diabetes increases risk of autism in offspring Article Text Causes and risk factors Growing evidence that maternal gestational diabetes increases risk of autism in offspring

2015 Evidence-Based Mental Health

118. Management of autism in children and young people: a good clinical practice guideline

Management of autism in children and young people: a good clinical practice guideline Management of autism in children and young people: a good clinical practice guideline Management of autism in children and young people: a good clinical practice guideline Veereman G, Holdt Henningsen K, Eyssen M, Benahmed N, Christiaens W, Bouchez M-H, De Roeck A, Deconinck N, De ligne G, Dewitte G, Gheysen T, Hendrix M, Kagan C, Magerotte G, Moonen M, Roeyers H, Schelstraete S, Soncarrieu M-V, Steyaert J (...) , Steyaert J, Tolfo F, Vrancken G, Willaye E, Wintgens A, Wouters S, Croonenberghs J. Management of autism in children and young people: a good clinical practice guideline. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 233. 2014 Authors' conclusions The GDG worked diligently in order to demonstrate which interventions are meaningful to improve the lives of children and young people with autism and their families. The problems faced by children and adolescents with autism, caretakers

2015 Health Technology Assessment (HTA) Database.

119. Addendum to the Notice on the Efficacy of Rehabilitative Interventions and Pharmacological Therapies for Children Aged 2 to 12 Years with Autism Spectrum Disorder (ASD)

Addendum to the Notice on the Efficacy of Rehabilitative Interventions and Pharmacological Therapies for Children Aged 2 to 12 Years with Autism Spectrum Disorder (ASD) Addenda à l'avis sur l'efficacité des interventions de réadaptation et des traitements pharmacologiques pour les enfants de 2 à 12 ans ayant un trouble du spectre de l'autisme (TSA) [Addendum to the notice on the efficacy of rehabilitative interventions and pharmacological therapies for children aged 2 to 12 Years with autism (...) spectrum disorder (ASD)] Addenda à l'avis sur l'efficacité des interventions de réadaptation et des traitements pharmacologiques pour les enfants de 2 à 12 ans ayant un trouble du spectre de l'autisme (TSA) [Addendum to the notice on the efficacy of rehabilitative interventions and pharmacological therapies for children aged 2 to 12 Years with autism spectrum disorder (ASD)] Mercier C, Beaudoin I Record Status This is a bibliographic record of a published health technology assessment from a member

2014 Health Technology Assessment (HTA) Database.

120. Therapies for Children With Autism Spectrum Disorder: Behavioral Interventions Update

Therapies for Children With Autism Spectrum Disorder: Behavioral Interventions Update Therapies for children with autism spectrum disorder: behavioral interventions update Therapies for children with autism spectrum disorder: behavioral interventions update Weitlauf AS, McPheeters ML, Peters B, Sathe N, Travis R, Aiello R, Williamson E, Veenstra-VanderWeele J, Krishnaswami S, Jerome R, Warren Z Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Weitlauf AS, McPheeters ML, Peters B, Sathe N, Travis R, Aiello R, Williamson E, Veenstra-VanderWeele J, Krishnaswami S, Jerome R, Warren Z. Therapies for children with autism spectrum disorder: behavioral interventions update. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 137. 2014 Authors' objectives We updated a prior systematic review

2014 Health Technology Assessment (HTA) Database.